查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600531

生物製药市场：按产品类型、服务、原料类型、应用划分 - 全球预测 2025-2030

Biopharmaceuticals Market by Product Type, Services, Raw Material Type, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生物製药市场估值为5,740.4亿美元，预计2024年将达到6,271.9亿美元，复合年增长率为9.74%，到2030年将达到11.0051亿美元。

生物製药产业包括生物来源药物和治疗方法的研究、开发和製造。该细分市场因其能够治疗癌症和自体免疫疾病等复杂疾病而发挥重要作用。对生物製药的需求在于其先进的功效和特异性，与传统药物相比，副作用更少，并提供个人化的治疗选择。最终用途包括疫苗、单株抗体以及细胞和基因治疗，范围包括医院、专科诊所和研究机构。

主要市场统计
基准年[2023] 5740.4亿美元
预测年份 [2024] 6271.9亿美元
预测年份 [2030] 1,100,510 百万美元
复合年增长率（%） 9.74%

市场成长主要由慢性病的增加、技术进步以及研发投资的增加所推动。此外，政府的支持政策和对有效治疗方法的需求不断增加也为产业相关人员创造了重大机会。生物相似药的开发是一项新的商机，它可以为昂贵的生物製药提供具有成本效益的替代品。此外，在药物发现和个人化医疗中使用人工智慧（AI）和机器学习可以缩短上市时间并提高治疗效果。

儘管预计将出现强劲成长，但生物製药市场面临研发成本高、製造流程复杂和监管要求严格等限制。市场进入障碍和智慧财产权问题等挑战正在阻碍成长和采用。为了解决这些问题，企业正在投资建立伙伴关係和研究合作，以加速研究、简化製造流程、利用人工智慧创新药物开发，并考虑开拓具有有利监管环境的新兴市场。

业务成长的创新领域包括 CRISPR 等基因编辑技术、新型药物传输系统、疫苗平台的扩展，尤其是 mRNA 技术。这些进步预计将彻底改变治疗模式并创造新的收益来源。市场竞争激烈、技术变革迅速、专业化程度高，需要策略敏捷性和持续创新才能保持领先并抓住新机会。

市场动态：揭示快速发展的生物製药市场的关键市场洞察

供需的动态交互作用正在改变生物製药市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性病盛行率和目标需求生物製药
    • 加大疫苗和药物研发投资
    • 有吸引力的生物製药报销政策
  • 市场限制因素
    • 原料供应链中断与药物开发成本上升
  • 市场机会
    • 生物製药製造和检测技术的进步
    • 生技药品和疫苗製造外包的新趋势
  • 市场问题
    • 药品生产的严格监管架构和耗时的临床测试

波特五力：驾驭生物製药市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解生物製药市场的外部影响

外部宏观环境因素在塑造生物製药市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解生物製药市场的竞争格局

生物製药市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵：生物製药市场供应商绩效评估

FPNV定位矩阵是评估生物製药市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的盛行率和标靶治疗的需求 生物製药
      • 加大疫苗和药物研发投资
      • 有吸引力的生物製药报销政策
    • 抑制因素
      • 原料供应链中断及药物开发高成本
    • 机会
      • 生物製药製造和检测技术的进步
      • 生技药品和疫苗製造外包的新趋势
    • 任务
      • 严格的药品生产法规结构和耗时的临床测试
  • 市场区隔分析
    • 产品类型：正在进行的倡议，以推动单株抗体领域的创新
    • 服务：需要进行药典和多药典实验室检查，以确保合规性
    • 原料类型：致力于开发强大的API用于疾病的诊断、治疗和缓解
    • 应用：需要透过改变生活方式来治疗心血管疾病
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化

第六章生物製药市场：依产品类型

  • 介绍
  • 单株抗体
  • 精製蛋白
  • 重组生长因子
  • 重组激素
  • 重组蛋白
  • 合成免疫调节剂
  • 疫苗

第七章生物製药市场：依服务分类

  • 介绍
  • 药典和多药典实验室测试
  • 客自订测试或客户特定检查
  • 临床检查

第八章生物製药市场：依原料类型

  • 介绍
  • 活性药物成分
  • 配方添加物

第九章生物製药市场：依应用分类

  • 介绍
  • 自体免疫疾病
  • 心血管疾病
  • 荷尔蒙失调
  • 免疫学
  • 发炎和感染疾病
  • 代谢紊乱
  • 神经系统疾病
  • 肿瘤学

第十章美洲生物药学市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太生物製药市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的生物製药市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 阿斯特捷利康将以 11 亿美元收购呼吸道融合病毒（RSV）疫苗开发商 Icosavax
    • 阿兹海默症治疗药物「LEQEMBI静脉静脉注射（Lecanemab）」12月20日在日本上市
    • 美国卫生与公众服务部 (HHS) 宣布与再生元 (Regeneron) 合作开发救生单株抗体的详细信息

公司名单

  • AbbVie Inc.
  • Avidea Technologies
  • Bayer AG
  • Thermo Fisher Scientific Inc.
  • Ferring Pharmaceuticals
  • Abbott Laboratories
  • LG Chem Life Sciences Innovation Center, Inc.
  • Ipsen Pharma
  • Novo Nordisk A/S
  • Amgen Inc.
  • BTL BIoTechno Labs Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • bioMerieux SA
  • Nordic BioSite
  • GlaxoSmithKline PLC
  • Novartis AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Abgenex
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • Takeda Pharmaceutical Company Limited
  • Bio-Techne Corporation
  • Biogen Inc.
Product Code: MRR-434CCDA05130

The Biopharmaceuticals Market was valued at USD 574.04 billion in 2023, expected to reach USD 627.19 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 1,100.51 billion by 2030.

The biopharmaceutical industry encompasses the research, development, and manufacturing of biological drugs and therapies derived from living organisms. This sector plays a critical role due to its capacity to treat complex diseases like cancer and autoimmune disorders. The necessity of biopharmaceuticals lies in their advanced efficacy and specificity, offering fewer side effects and personalized treatment options compared to traditional pharmaceuticals. Applications include vaccines, monoclonal antibodies, and cell and gene therapies, with end use spanning hospitals, specialty clinics, and research institutes.

KEY MARKET STATISTICS
Base Year [2023] USD 574.04 billion
Estimated Year [2024] USD 627.19 billion
Forecast Year [2030] USD 1,100.51 billion
CAGR (%) 9.74%

Market growth is primarily driven by the increasing prevalence of chronic diseases, technological advancements, and heightened investments in R&D. Additionally, supportive government policies and growing demand for effective therapies create substantial opportunities for industry players. One emerging opportunity lies in the development of biosimilars, which can offer cost-effective alternatives to expensive biopharmaceuticals. Another potential area is leveraging artificial intelligence (AI) and machine learning for drug discovery and personalized medicine, which can reduce time-to-market and enhance treatment efficacy.

Despite robust growth prospects, the biopharma market faces limitations, including high R&D costs, complex manufacturing processes, and stringent regulatory requirements. Challenges like market access barriers and intellectual property issues further hinder growth and adoption. To address these, firms should consider investing in partnerships and collaborations that can accelerate research and streamline production processes, utilize AI to innovate drug development, and explore emerging markets with favorable regulatory scenarios.

Innovative areas for business growth include gene editing technologies like CRISPR, novel drug delivery systems, and expanding vaccine platforms, especially mRNA technology. These advancements promise to revolutionize treatment paradigms and create new revenue streams. The market is characterized by intense competition, rapid technological shifts, and a high degree of specialization, necessitating strategic agility and continuous innovation to maintain leadership and capture emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopharmaceuticals Market

The Biopharmaceuticals Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
    • Rising Investments in Vaccine and Drugs Development
    • Attractive Reimbursement Policies for Biopharmaceuticals
  • Market Restraints
    • Raw Material Supply Chain Disruptions and High Cost of Drug Development
  • Market Opportunities
    • Advancements in Biopharmaceutical Manufacturing and Testing Technologies
    • Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
  • Market Challenges
    • Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials

Porter's Five Forces: A Strategic Tool for Navigating the Biopharmaceuticals Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopharmaceuticals Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopharmaceuticals Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopharmaceuticals Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopharmaceuticals Market

A detailed market share analysis in the Biopharmaceuticals Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopharmaceuticals Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopharmaceuticals Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Avidea Technologies, Bayer AG, Thermo Fisher Scientific Inc., Ferring Pharmaceuticals, Abbott Laboratories, LG Chem Life Sciences Innovation Center, Inc., Ipsen Pharma, Novo Nordisk A/S, Amgen Inc., BTL Biotechno Labs Pvt. Ltd., Johnson & Johnson Services, Inc., Pfizer, Inc., bioMerieux SA, Nordic BioSite, GlaxoSmithKline PLC, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Sanofi S.A., Abgenex, AstraZeneca PLC, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Bio-Techne Corporation, and Biogen Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Monoclonal Antibodies, Purified Proteins, Recombinant Growth Factors, Recombinant Hormone, Recombinant Proteins, Synthetic Immunomodulators, and Vaccines.
  • Based on Services, market is studied across Compendial & Multi Compendial Laboratory Testing, Custom Testing or Customer Proprietary Testing, and Laboratory Testing.
  • Based on Raw Material Type, market is studied across Active Pharmaceutical Ingredient and Formulation Excipients.
  • Based on Application, market is studied across Autoimmune Disorders, Cardiovascular Diseases, Hormonal Disorders, Immunology, Inflammatory & Infectious Diseases, Metabolic Disorders, Neurological Diseases, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
      • 5.1.1.2. Rising Investments in Vaccine and Drugs Development
      • 5.1.1.3. Attractive Reimbursement Policies for Biopharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. Raw Material Supply Chain Disruptions and High Cost of Drug Development
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Biopharmaceutical Manufacturing and Testing Technologies
      • 5.1.3.2. Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Ongoing R&D initiatives to promote innovations in the field of monoclonal antibodies
    • 5.2.2. Services: Need for compendial & multi compendial laboratory testing to ensure compliance with regulations
    • 5.2.3. Raw Material Type: Efforts to develop potent APIs to diagnose, cure, or mitigate disease conditions
    • 5.2.4. Application: Changes in lifestyles leading to the need for treatment strategies for cardiovascular diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Biopharmaceuticals Market, by Product Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Purified Proteins
  • 6.4. Recombinant Growth Factors
  • 6.5. Recombinant Hormone
  • 6.6. Recombinant Proteins
  • 6.7. Synthetic Immunomodulators
  • 6.8. Vaccines

7. Biopharmaceuticals Market, by Services

  • 7.1. Introduction
  • 7.2. Compendial & Multi Compendial Laboratory Testing
  • 7.3. Custom Testing or Customer Proprietary Testing
  • 7.4. Laboratory Testing

8. Biopharmaceuticals Market, by Raw Material Type

  • 8.1. Introduction
  • 8.2. Active Pharmaceutical Ingredient
  • 8.3. Formulation Excipients

9. Biopharmaceuticals Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Disorders
  • 9.3. Cardiovascular Diseases
  • 9.4. Hormonal Disorders
  • 9.5. Immunology
  • 9.6. Inflammatory & Infectious Diseases
  • 9.7. Metabolic Disorders
  • 9.8. Neurological Diseases
  • 9.9. Oncology

10. Americas Biopharmaceuticals Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biopharmaceuticals Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biopharmaceuticals Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
    • 13.3.2. LEQEMBI Intravenous Infusion (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
    • 13.3.3. HHS Announces Details of Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Avidea Technologies
  • 3. Bayer AG
  • 4. Thermo Fisher Scientific Inc.
  • 5. Ferring Pharmaceuticals
  • 6. Abbott Laboratories
  • 7. LG Chem Life Sciences Innovation Center, Inc.
  • 8. Ipsen Pharma
  • 9. Novo Nordisk A/S
  • 10. Amgen Inc.
  • 11. BTL Biotechno Labs Pvt. Ltd.
  • 12. Johnson & Johnson Services, Inc.
  • 13. Pfizer, Inc.
  • 14. bioMerieux SA
  • 15. Nordic BioSite
  • 16. GlaxoSmithKline PLC
  • 17. Novartis AG
  • 18. Eli Lilly and Company
  • 19. Merck & Co., Inc.
  • 20. Bristol-Myers Squibb Company
  • 21. Sanofi S.A.
  • 22. Abgenex
  • 23. AstraZeneca PLC
  • 24. F. Hoffmann-La Roche AG
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Bio-Techne Corporation
  • 27. Biogen Inc.

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOPHARMACEUTICALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOPHARMACEUTICALS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PURIFIED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SYNTHETIC IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COMPENDIAL & MULTI COMPENDIAL LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CUSTOM TESTING OR CUSTOMER PROPRIETARY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY FORMULATION EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY & INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 200. BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023